Phase 4 N=149 Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution
Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution
Primary: Blood Albumin — 4.02 g/L — p=<0.0125
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=4 L-Carnitine in Peritoneal Dialysis
End-Stage Renal Disease
Primary: Long Dwell Ultrafiltration — 2167 milliliters
Phase 3 N=121 Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis
Anemia
Primary: Mean Change From Baseline to the Highest Hemoglobin up to Day 71 — 1.3; .7 g/dL
Phase 2 N=20 Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis
Chronic Renal Failure
Primary: Change in Daily Urine Volume From Baseline — 18.3 mL
N/A N=223 Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis
Renal Impairment · Renal Anemia of Chronic Kidney Disease
Primary: Percentage of Participants With Hemoglobin Values in the Range of 11-12 Grams Per Deciliter (g/dL) During the Evaluation Period of Visit 7 (Month 7) to Visit 9 (Month 9)…
Phase 3 N=251 Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
End Stage Renal Disease (ESRD) · Diabetes · CAPD
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
Phase 3 N=42 Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease
Primary: Mean Hb Level of Week 20 and Week 24 — 11.35 g/dL
N/A N=64 Treatment of Peritonitis in Automated Peritoneal Dialysis
Secondary Peritonitis
Primary: Peritonitis Resolved — 26; 29 participants — p=<0.05
Phase 2 N=59 Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.
Anemia
Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 11.22; 11.33; 0.10 g/dL
Phase 4 N=60 Study to Evaluate the Effects Icodextrin Versus Dianeal on Insulin Resistance in Nondiabetic Automated Peritoneal Dialysis Patients
Disorders Associated With Peritoneal Dialysis
Primary: Adjusted HOMA Index Score at 3 Months Using Baseline Values as a Covariate and Groups as the Fixed Factor — 1.49; 1.89 IR score
Phase 3 N=251 IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
ESRD · Diabetes
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
Phase 4 N=7 Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
Continuous Ambulatory Peritoneal Dialysis · End Stage Renal Disease
Primary: Volume of Distribution, Central Compartment (Vc) — 2.78 Liters (L)
Phase 4 N=251 IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
ESRD · Diabetes · CAPD
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
N/A N=73 Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass
Acute Kidney Injury
Primary: Number of Participants With Negative Fluid Balance on Postop Day 1 — 21; 29 Participants
N/A N=11 Acid-Base Composition With Use of hemoDialysates
End Stage Renal Disease
Primary: Peridialytic Arterialized Blood Bicarbonate Concentrations — 25.7; 27.1; 27.2; 27.4 mEq/l — p=<0.0001
Phase 2 N=131 Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis
End-Stage Renal Disease (ESRD)
Primary: Percent of Subjects Whose Hemoglobin (Hgb) Decreases by a Total of 1.0 Grams/ Deciliter (g/dL) (or More) From Baseline on Each of Two Successive Measurements. — 5; 6; 5…
Phase 4 N=17 Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients
Peritoneal Dialysis Complication · Hyperphosphatemia · Hypoalbuminemia
Primary: Serum Phosphate at Baseline — 7.47 mg/dL
Phase 4 N=10 Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients
Infectious Peritonitis
Primary: Determine Dalbavancin Plasma Area Under the Curve in Peritoneal Dialysis Patients After Intravenous and Intraperitoneal Administration — 40573.2; 13532.3 mg*h/L
N/A N=18 Observational Study of Citrate Based Dialysis in Pediatric Patients Receiving Hemodialysis
Complication of Dialysis
Primary: Dialyzer Clotting Rate — 6 percentage of total treatments
N/A N=671 Prevention of Peritonitis in Peritoneal Dialysis
Kidney Failure, Chronic · Peritoneal Dialysis-associated Peritonitis · Dialysis Capd Infection
Primary: Time to the First Dialysis-associated Peritonitis Episode in the Retraining Group and the Control Group — 381; 368 Days to first peritonitis episode — p=0.51
N/A N=12 Comparative Effects Of Dialysate Flow Rate And Membrane Packing On The Performance Of Dialyzers Used For Hemodialysis
Chronic Kidney Disease · Chronic Renal Disease
Primary: Effect of Increased Dialysate Flow Rate on KoA for Urea Between 4 Dialyzers With Different Membrane Packing Densities. — 844; 763; 770; 798 KoA for urea (mL/min)
Phase 3 N=305 Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
Renal Failure Chronic Requiring Hemodialysis
Primary: Change From Baseline Hemoglobin at End-of-Treatment: Least-Squares Mean — 0.6; -3.0 grams per liter — p=0.011
N/A N=1,075 Quality of Life and Depression in Dialysis Patients
Chronic Kidney Disease Stage 5
Primary: Change of Kidney Disease Quality of Life Short Form 1.3 (KDQOL SF 1.3) Score and Beck Depression Inventory(BDI) Score From Visit 1 Period — 1.22; -1.50; 1.62; 0.46 units…
Phase 3 N=161 A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Hemodialysis Patients With Hyperphosphatemia
Primary: Incidence of Adverse Events — 152 Participants
Phase 2 N=114 Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA
Anemia · Chronic Renal Failure · Chronic Kidney Disease
Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 9.34; 9.20; 9.07; 11.45 g/dL
Phase 3 N=806 Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection
Kidney Failure, Chronic · Catheter-Related Infections
Primary: Presence of a CAC-Adjudicated Catheter-Related Bloodstream Infection (CRBSI) in Subjects Receiving Hemodialysis for the Treatment of End Stage Renal Disease (ESRD)…
N/A N=10 Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis
End-Stage Renal Disease
Primary: Safety as Evaluated by Rate and Severity of Treatment-emergent AEs (TEAEs) — 1; 0; 0; 0 Participants
Phase 1 N=8 Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis
Anaemia
Primary: Area Under the Concentration-time Curve (AUC) Over the Dosing Interval (AUC[0-tau]) of GSK1278863 and Its Metabolites — 184.9863; 138.6511; 162.9366; 131.2826 Hour into…
N/A N=19 Pilot Study of Nutrition in Maintenance Hemodialysis Patients
End-Stage Renal Disease · Meals · Hemodialysis
Primary: Hypotensive Event Frequency — 18; 13 events
N/A N=140 Dietary Education Intervention Impact on Dietary Protein Intake in PD
Dietary Modification
Primary: Normalized Protein Catabolic Rate (nPCR) — 1.038; 0.930 g/(kg*d)